medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2014, Number 3

<< Back Next >>

Residente 2014; 9 (3)

Dislipidemia en lupus eritematoso sistémico

González-Ponce F, Flores-Chávez A, Dávalos-de la Cruz AP, Rodríguez-Hernández TM, Trujillo-Trujillo X, Aguilar-Ríos EG, Araujo-López A, González-López L

Language: Spanish
References: 55
Page: 95-105
PDF size: 266.32 Kb.


ABSTRACT

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoinmune disease characterized by the presence of antibodies that attach to the tissue of various organs, affecting their functionality. The mortality in SLE has become related more with cardiovascular diseases than to infections associated with the disease due to inflammatory agents, use of certain drugs and improper lifestyle. Dyslipidemia is an asymptomatic condition characterized by an alteration in the concentration of lipoproteins in the blood, and is one of the five most frequently comorbidities present in SLE. Factors that may increase the risk of a patient with SLE to develop dyslipidemia include the prevalence of central adiposity, nephrotic syndrome also related to SLE, diabetes mellitus, thyroid disease, smoking, sedentary lifestyle, family history of cardiovascular disease before the age of 55 years, early menopause, and use of medications such as corticosteroids and immunosuppressive drugs. The reason that this comorbidity may occur is due to the destruction of apolipoproteins by the same autoinmune cells, causing protein catabolism of chylomicrons and of lipoprotein lipase enzyme, bringing the change in the levels of fatty acids in the plasma. Regarding treatment, emphasis is placed on changes in lifestyle that lead to loss of abdominal fat, integral nutritional management and drug therapy. The initial assessment should be performed in this group from the age of 20 years, and should be monitored annually. If dyslipidemia is detected, monitoring should be performed every 6 to 8 weeks. It is important for the doctor to know more about the treatment, since its importance in a patient with dyslipidemia is not only to lower his blood lipid profile, but to increase his quality of life.


REFERENCES

  1. Borba EF, Carvalho JF, Bonfa E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clinical & Developmental Inmunology. 2006; 13(2-4): 203-208.

  2. Gómez-Puerta JA, Cervera R. Lupus eritematoso sistémico. Medicina & laboratorio. 2008; 14: 211-223.

  3. Enríquez-Mejía MG. Fisiopatología del lupus eritematoso sistémico. Revista de Medicina e Investigación. 2013; 1 (1): 8-16.

  4. Pelaéz-Ballestas I, Sanin LH, Moreno-Montoya J et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. The Journal of Rheumatology. 2011; 38 (86): 3-8.

  5. Morales-Romero J, Cazárez-Méndez JM, Gámez-Nava JI, Triano-Páez M, Villa-Manzano AI, López-Olivo MA et al. La atención médica en reumatología en un hospital de segundo nivel de atención. Reumatol Clin. 2005; 1 (2): 87-94.

  6. D’Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007; 369: 587-596.

  7. Elliot JR, Manzi S. Cardiovascular risk assessment and treatment in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2009; 23: 481-494.

  8. Magro-Checa C, Salvatierra J, Rosales-Alexander JL. Riesgo cardiovascular en el lupus eritmatoso sistémico: factores implicados y métodos para su valoración. Semin Fund Esp Reumatol. 2012; 13 (3): 95-102.

  9. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006; 54: 2550-2557.

  10. Canalizo-Miranda E, Favela-Pérez EA, Salas-Anaya JA, Gómez-Díaz R, Jara-Espino R, Torres-Arreola LP et al. Guía de práctica clínica diagnóstico y tratamiento de las dislipidemias. Rev Med Inst Mex Seguro Soc. 2013; 51 (6): 700-709.

  11. Jonas A. Lipoprotein structure. Elsevier Science. 2002; 18: 483-504.

  12. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 2004; 255: 188-205.

  13. Wijaya LK, Iwanoff Y, Sukmana N, Subekti I, Prihartono J. The proportion of dyslipidemia in systemic lupus erythematosus patient and distribution or correlated factors. University of Indonesia. 2005; 37 (3): 132-144.

  14. Miguel-Roca PE. Dislipidemias. ACIMED. 2009; 20 (6): 265-273.

  15. The Expert Panel. Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adults Treatment Panel III). Final report. Circulation. 2002; 106: 3143-3421.

  16. Murguía-Miranda C, Sánchez-Barrera RG, Hernández-Saavedra D, Cruz-López M. Prevalencia de dislipidemias en una población de sujetos en apariencia sanos y su relación con la resistencia a la insulina. Salud Pública Mex. 2008; 50: 375-382.

  17. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernandez S, Franco A, Cuevas-Nasu L et al. Encuesta Nacional de Salud y Nutricion 2012. Resultados Nacionales. Cuernavaca, Mexico: Instituto Nacional de Salud Pública (MX), 2012.

  18. Molina MJ, Mayor AM, Morell AEF, Lopez MA, Vila LM. Prevalence of systemic lupus erythematosus and associated comorbidities in Puerto Rico. J Clin Rheumatol. 2007; 13 (4): 202-204.

  19. Nuttall SL, Heaton S, Piper MK, Martin U, Gordon C. Cardiovascular risk in systemic lupus erythematosus –evidence of increased oxidative stress and dyslipidaemia. British Society for Rheumatology. 2003; 42: 758-762.

  20. Cardaval RAM, Martínez JE, Mazzolin MA, Barros RGT, de-Almeida FA. Assessment of the risk of coronary heart disease in women with systemic lupus erythematosus. Bras J Rheumatol. 2009; 49 (6): 658-669.

  21. Amaya-Amaya J, Sarmiento-Monroy JC, Caro-Moreno J, Molano-González N, Mantilla RD, Rojas-Villarraga A et al. Caridiovascular disease in Latin American patients with systemic lupus erythematosus: A cross-sectional study and a systematic review. Autoinmune Diseases. 2013; 1: 1-20.

  22. Albar Z, Wijaya LK. Is there a relationship between serum C reactive protein level and dyslipideaemia in systemic lupus erythematosus? Acta Med Indones-indones J Intern Med. 2006; 38 (1): 23-28.

  23. Mikdashi J, Handwerger B, Langerberg P, Miller M, Kittner S. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke. 2007; 38: 281-285.

  24. Svenungsson E, Gunnarsson I, Fei GZ et al. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor a/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis & Rheumatism. 2003; 48 (9): 2533-2540.

  25. Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998; 338 (17): 1202-1211.

  26. Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. J Am Soc Nephrol. 2006; 17 (4): S145-147.

  27. Mooradian AD, Haas MJ, Wong NC. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes. 2004; 53: 513-520.

  28. Bakker O, Hudig F, Meijssen S, Wiersinga WM. Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem Biophys Res Commun. 1998; 249: 517-521.

  29. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C et al. Traditional Framingham risk factors fail to fully account for accelerated aterosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001; 44: 2331-2337.

  30. Ramírez-Vallejo E. Dislipidemias secundarias. Segundo consenso nacional sobre detección, evaluación y tratamiento de las dislipoproteinemias en adultos. Revista Colombiana de Cardiología. 2005; 11 (2): 433-436.

  31. Sabada B. Monitorización y efectos secundarios de los inmunosupresores en el transplante. An Sist Sanit Navar. 2006; 29 (2): 207-218.

  32. Wallace DJ, Metzger AL, Stecher VJ, Tumbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids. Am J Med. 1990; 89: 322-326.

  33. Illowite NT, Samuel P. Ginzler E, Jacobson MS. Dislipoproteinemia in pediatric systemic lupus erythematosus. Arhritis Rheym. 1988; 31: 859-863.

  34. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effects of corticosteroids. Am J Med. 1987; 83: 503-508.

  35. Ettinger WH, Hazzard WR. Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab. 1988; 67: 425-428.

  36. Petri M, Lakatta C, Magner L, Goldman D. Effect of prednison and hydroxychloroqine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med. 1994; 96: 254-259.

  37. Goldberg IJ. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996; 37: 693-707.

  38. Borba EF, Bonfa E, Vinagre CG et al. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum. 2000; 43: 1033-1040.

  39. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med. 1985; 161: 984-995.

  40. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259: 87-91.

  41. Enholm C, Aho K, Huttunen JK et al. Effect of interferon on plasma lipoproteins and on the activity of postheparin lipases. Arteriosclerosis. 1982; 2 (1): 69-73.

  42. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes. 1999; 107: 119-125.

  43. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340 (6): 448-454.

  44. Asanuma Y, Chung CP, Oeser A et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: Relationship to cardiovascular risk factors. J Rheumatol. 2006; 33 (3): 539-545.

  45. Pou J, Rebollo A, Alegret M. El monocito/macrófago como diana terapéutica en la aterosclerosis. Clin Invest Arterioscl. 2007; 19 (2): 92-108.

  46. Ministry of Health. Clinical Practice Guidelines. Lipids. Singapore: Ministry of Health; 2006.

  47. Scott M, Grundy MD, Becker D, Clark LT, Cooper RS, Denke MA et al. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood colesterol in Adults. Adult Treatment Panel III. NIH, 2002; 2:V1-V28.

  48. Castro-González MI. Ácidos grasos omega 3: Beneficios y fuentes. Redalyc. 2002; 27 (3): 128-136.

  49. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009; 25 (10): 567-579.

  50. American Dietetic Association. Disorders of lipid metabolism. Evidence-based nutrition practice guideline. Chicago (IL): American Dietetic Association; 2011.

  51. Escudero-Alvarez E, González-Sanchez P. La fibra dietética. Nutr Hosp. 2006; 21 (2): 61-72.

  52. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR et al. ESC/EAS guidelines for the management of dislipidemias: the Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Association for Cardiovascular Prevention & Rehabilitation. Eur Hearth J. 2011; 32: 1769-1818.

  53. Grundy SM, Cleeman JI, Bairey N, Brewer B, Clark L, Hunninghake D et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb Vasc Biol. 2004; 24: e149-61.

  54. Tapia-Conyer R. Norma Oficial Mexicana NOM-037-SSA2-2002, para la prevencion, tratamiento y control de las dislipidemias.

  55. Nestel PJ, O’Brien R, Nelson M. Management of dyslipidaemia. Evidence and practical recommendations. Australian Family Physician. 2008; 37 (7): 521-527.




2020     |     www.medigraphic.com